Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the WATCHMAN Left Atrial Appendage (LAA) Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Paroxysmal, persistent or permanent non-valvular AF~* Eligible for long-term warfarin therapy~* Eligible to come off warfarin therapy~* Calculated CHADS2 score of 2 or greater. Also patients with a CHADS2 score of 1 may be included if any of the following apply:~  * Female age 75 or older~ * Baseline LVEF ≥ 30 and \< 35%~ * Aged 65-74 and has diabetes or coronary artery disease~ * Aged 65 or greater and has congestive heart failure~Key Exclusion Criteria:~* Contraindicated/allergic to aspirin~* Indicated for clopidogrel therapy or has taken clopidogrel within 7 days prior to enrollment~* History of atrial septal repair or has an ASD/PFO device~* Implanted mechanical valve prosthesis~* NYHA Class IV CHF~* Resting heart rate \> 110 bpm~* Participated previously in the PROTECT AF or CAP Registry studies~Key Echo Exclusion Criteria:~* LVEF \< 30%~* Existing pericardial effusion \> 2mm~* High risk PFO~* Significant mitral valve stenosis~* Complex atheroma with mobile plaque of the descending aorta and/or aortic arch~* Cardiac tumor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- WATCHMAN (Type: EXPERIMENTAL): Subjects assigned to receive the WATCHMAN device.
- Warfarin (Type: ACTIVE_COMPARATOR): Subjects assigned to warfarin therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).